礼来(LLY.US)重磅新药“替尔泊肽”在中国申报第五项上市申请

智通财经
15 Dec 2024

智通财经APP获悉,12月14日,中国国家药监局药品审评中心(CDE)网站最新公示,礼来(LLY.US)重磅药物GIP/GLP-1受体双重激动剂替尔泊肽注射液新适应症上市申请获得受理,具体适应症尚未披露。根据CDE官网查询,这是替尔泊肽在中国递交的第五项上市申请,其中两项上市申请此前已经获NMPA批准。

替尔泊肽(tirzepatide)是一款葡萄糖依赖性促胰岛素多肽(GIP)和胰高血糖素样肽-1(GLP-1)受体激动剂,每周一次注射。目前,礼来也持续不断探索替尔泊肽在各种适应症上的应用。

根据礼来官网的管线资料,替尔泊肽还针对多项适应症处于3期临床研究阶段,包括用于降低肥胖的发病率和死亡率、减少2型糖尿病患者的不良CV结局等。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10